FEDERAL JURY AWARDS $2M TO PLAINTIFF IN FIRST SURGICAL MESH TRIAL
Written By: Rheingold, Giuffra, Ruffo & Plotkin LLP
By Thamanna Hussain
Our pelvic mesh litigation trial lawyers are encouraged by a federal jury awarded a total of $2 million in damages to a plaintiff who claimed that C.R. Bard Inc. had failed to warn of the potential risks associated with its Avaulta-branded transvaginal mesh device. Donna Cisson, the patient, stated that the defective device permanently injured her and required her to undergo several revision surgeries to have it removed.
After 12 hours of deliberation, the six jurors rendered their decision against New Jersey-based C.R. Bard, the manufactures of the Avaulta line of devices used to treat pelvic organ prolapse. The jury awarded Cisson a total of $250,000 in compensatory damages and $1.75 million in punitive damages.
The trial began on July 29, in the U.S. District Court for the Southern District of West Virginia, and is the first federal case among more than 28,000 pending in this federal court that claim the medical device was not suitable for human implantation. Cisson's lawsuit is one of the four bellwether cases that U.S. District Judge Joseph Goodwin will hear to determine the next step in litigation for the remaining lawsuits.
Thousands of individuals have been injured as a result of such mesh implants, which can erode, cause infections, pain, bleeding and require several removal surgeries. In many cases, the mesh cannot be removed entirely because the device is intended to be a permanent implant. At Rheingold, Giuffra, Ruffo & Plotkin LLP, our attorneys have successfully handled numerous transvaginal mesh lawsuits and have won many verdicts and settlements for people who have suffered. If you or someone close to you been harmed by a Bard Avaulta Transvaginal Mesh, please contact our firm.